Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with Subclinical Myocardial Remodeling in Patients with Type 2 Diabetes: A Cross-sectional Study in China

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2020 Oct 8

PMID 33030804

Citations 5

Authors

Nengguang Fan

Xiaoying Ding

Qin Zhen

Liping Gu

Aifang Zhang

Tingting Shen

Yufan Wang

Yongde Peng

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: Non-alcoholic fatty liver disease, especially with liver fibrosis, is associated with cardiovascular diseases. The Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS), a non-invasive marker of advanced fibrosis, was found to be associated with cardiovascular diseases in different populations. The aim of the present study was to determine whether the NFS is associated with subclinical myocardial remodeling in type 2 diabetes patients.

Materials And Methods: A cross-sectional study was carried out in type 2 diabetes patients. The NFS derived from available parameters was calculated, and the participants were divided according to the quartiles of the NFS and grades of the NFS (low, intermediate and high). Fibrosis-4 and Aspartate Aminotransferase to Platelet Ratio Index, another two liver fibrosis scores, were also calculated. Subclinical myocardial remodeling was examined by echocardiography, and its associations with NFS, Fibrosis-4 and Aspartate Aminotransferase to Platelet Ratio Index were analyzed.

Results: A total of 1,878 type 2 diabetes patients were enrolled in the present study. The NFS was independently associated with sex, age, body mass index, low-density lipoprotein cholesterol and glycated hemoglobin in type 2 diabetes patients. Parameters of subclinical myocardial remodeling including left atrial dimension, interventricular septum thickness, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular posterior wall thickness (LVPWT) and left ventricular mass index were all gradually increased with the increment of the NFS. Linear regression analysis further showed that the NFS was positively associated with left atrial dimension, interventricular septum thickness, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, LVPWT and left ventricular mass index after adjustment for the confounding factors. Similarly, Fibrosis-4 was associated with left atrial dimension, interventricular septum thickness, LVPWT and left ventricular mass index. In contrast, the Aspartate Aminotransferase to Platelet Ratio Index was only associated with LVPWT.

Conclusions: Non-invasive liver fibrosis scores, especially the NFS, are independently associated with subclinical myocardial remodeling in type 2 diabetes patients.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes.

Cernea S, Onisor D, Roiban A, Benedek T, Rat N World J Cardiol. 2024; 16(10):580-594.

PMID: 39492975 PMC: 11525805. DOI: 10.4330/wjc.v16.i10.580.

Association between cardiometabolic index and hepatic steatosis and liver fibrosis: a population-based study.

Cheng L, Wu Q, Wang S Hormones (Athens). 2024; 23(3):477-486.

PMID: 38861108 DOI: 10.1007/s42000-024-00572-9.

Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease.

Yang A, Jung N, Kim S, Lee J Front Pediatr. 2022; 10:825141.

PMID: 35223701 PMC: 8866638. DOI: 10.3389/fped.2022.825141.

Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?.

Perdomo C, Garcia-Fernandez N, Escalada J J Clin Med. 2021; 10(9).

PMID: 34068699 PMC: 8126096. DOI: 10.3390/jcm10092040.

Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross-sectional study in China.

Fan N, Ding X, Zhen Q, Gu L, Zhang A, Shen T J Diabetes Investig. 2020; 12(6):1035-1041.

PMID: 33030804 PMC: 8169360. DOI: 10.1111/jdi.13430.

References

Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M . Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013; 12:124. PMC: 3766150. DOI: 10.1186/1475-2840-12-124. View

Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y . Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016; 46(9):862-70. DOI: 10.1111/hepr.12647. View

Sheka A, Adeyi O, Thompson J, Hameed B, Crawford P, Ikramuddin S . Nonalcoholic Steatohepatitis: A Review. JAMA. 2020; 323(12):1175-1183. DOI: 10.1001/jama.2020.2298. View

Kim D, Kim W, Kim H, Therneau T . Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2012; 57(4):1357-65. PMC: 3622816. DOI: 10.1002/hep.26156. View

Long M, Pedley A, Massaro J, Hoffmann U, Fox C . The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. PLoS One. 2016; 11(6):e0157517. PMC: 4920364. DOI: 10.1371/journal.pone.0157517. View

Younossi Z, Golabi P, de Avila L, Paik J, Srishord M, Fukui N . The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019; 71(4):793-801. DOI: 10.1016/j.jhep.2019.06.021. View

Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Akita T . Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2018; 1(9):899-910. PMC: 5721461. DOI: 10.1002/hep4.1105. View

Li S, Zhu Z, Xue M, Yi X, Liang J, Niu C . Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(6):1241-1252. DOI: 10.1016/j.bbadis.2019.01.019. View

Chen Q, Li Q, Li D, Chen X, Liu Z, Hu G . Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis. 2020; 299:45-52. DOI: 10.1016/j.atherosclerosis.2020.03.010. View

10.

Lee H, Kim G, Choi Y, Huh B, Lee B, Kang E . Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Diabetes Metab J. 2019; 44(2):267-276. PMC: 7188976. DOI: 10.4093/dmj.2019.0001. View

11.

Unalp-Arida A, Ruhl C . Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017; 66(1):84-95. PMC: 7005915. DOI: 10.1002/hep.29113. View

12.

Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015; 16(3):233-70. DOI: 10.1093/ehjci/jev014. View

13.

Yoshihisa A, Sato Y, Yokokawa T, Sato T, Suzuki S, Oikawa M . Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2017; 5(2):262-270. PMC: 5880657. DOI: 10.1002/ehf2.12222. View

14.

Kim J, Moon J, Byun S, Lee J, Kang D, Sung K . Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. Cardiovasc Diabetol. 2020; 19(1):51. PMC: 7196226. DOI: 10.1186/s12933-020-01025-4. View

15.

Chen Y, Xu M, Wang T, Sun J, Sun W, Xu B . Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis. 2015; 241(1):145-50. DOI: 10.1016/j.atherosclerosis.2015.05.002. View

16.

Fan N, Ding X, Zhen Q, Gu L, Zhang A, Shen T . Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross-sectional study in China. J Diabetes Investig. 2020; 12(6):1035-1041. PMC: 8169360. DOI: 10.1111/jdi.13430. View

17.

Siddiqui M, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C . Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clin Gastroenterol Hepatol. 2019; 17(9):1877-1885.e5. PMC: 6609497. DOI: 10.1016/j.cgh.2018.12.031. View

18.

Baratta F, Pastori D, Angelico F, Balla A, Paganini A, Cocomello N . Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. Clin Gastroenterol Hepatol. 2019; 18(10):2324-2331.e4. DOI: 10.1016/j.cgh.2019.12.026. View

19.

Ismaiel A, Dumitrascu D . Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne). 2019; 6:202. PMC: 6763690. DOI: 10.3389/fmed.2019.00202. View

20.

Simon T, Bamira D, Chung R, Weiner R, Corey K . Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity (Silver Spring). 2017; 25(8):1313-1316. PMC: 5648006. DOI: 10.1002/oby.21879. View